

TDMS No. 20201 - 01

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)
WITH AVERAGE SEVERITY GRADES[b]**

Date Report Reqsted: 06/14/2006

Test Type: 26-WEEK

TEF TRANSGENICS (TCDD)

Time Report Reqsted: 13:12:56

Route: SKIN APPLICATION

CAS Number: 1746-01-6

First Dose M/F: NA / 04/21/03

Species/Strain: MICE/TG.AC HEMI

Lab: BAT

C Number: C20201A

Lock Date: 07/24/2004

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include 001 0 NG/KG

Include 002 121 NG/KG

Include 003 760 NG/KG

Test Type: 26-WEEK

TEF TRANSGENICS (TCDD)

Time Report Requested: 13:12:56

Route: SKIN APPLICATION

CAS Number: 1746-01-6

First Dose M/F: NA / 04/21/03

Species/Strain: MICE/TG.AC HEMI

Lab: BAT

0 NG/KG	121 NG/KG	760 NG/KG
Disposition Summary		
Animals Initially in Study	20	20
Early Deaths		
Moribund Sacrifice	1	6
Natural Death	2	2
Survivors		
Terminal Sacrifice	17	12
Animals Examined Microscopically	20	20
ALIMENTARY SYSTEM		
Liver	(20)	(20)
Clear Cell Focus	1	
Fatty Change	1 [1.0]	4 [1.0]
Hematopoietic Cell Proliferation	1 [1.0]	4 [1.3]
Hepatodiaphragmatic Nodule	1	
Inflammation	19 [1.2]	19 [1.2]
Myelodysplasia		2 [2.0]
Necrosis	7 [1.6]	9 [1.4]
Pigmentation	10 [1.0]	9 [1.0]
Tension Lipidosis		15 [1.3]
Centrilobular, Vacuolization Cytoplasmic Hepatocyte, Degeneration		1 [3.0]
Mesentery	(1)	(0)
Fat, Necrosis	1 [3.0]	1 [3.0]
Salivary Glands	(1)	(0)
Stomach, Forestomach	(6)	(4)
Hyperplasia		2 [2.5]
Stomach, Glandular	(1)	(0)
Glands, Hyperplasia	1 [2.0]	1 [2.0]
Tooth	(6)	(6)
Malformation		1
CARDIOVASCULAR SYSTEM		
Heart	(0)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

TEF TRANSGENICS (TCDD)

Time Report Requested: 13:12:56

Route: SKIN APPLICATION

CAS Number: 1746-01-6

First Dose M/F: NA / 04/21/03

Species/Strain: MICE/TG.AC HEMI

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	121 NG/KG	760 NG/KG
Inflammation, Chronic Active Thrombosis		1 [3.0]	1 [2.0] 1 [3.0]
ENDOCRINE SYSTEM			
None			
GENERAL BODY SYSTEM			
None			
GENITAL SYSTEM			
None			
HEMATOPOIETIC SYSTEM			
Lymph Node	(0)	(0)	(1)
Lymph Node, Mandibular Hyperplasia, Lymphoid	(0)	(1) 1 [2.0]	(2) 2 [2.5]
Spleen	(20)	(20)	(20)
Hematopoietic Cell Proliferation Myelodysplasia	3 [1.3]	9 [1.7]	11 [2.3] 2 [2.0]
Thymus	(20)	(19)	(19)
Atrophy	3 [2.7]	3 [3.0]	5 [2.4]
INTEGUMENTARY SYSTEM			
Skin	(4)	(2)	(6)
Cyst Epithelial Inclusion			1
Fibrosis	1 [2.0]		
Hyperplasia, Squamous	4 [1.8]		
Inflammation, Chronic Active	3 [1.3]	1 [2.0]	4 [2.5]
Ulcer	1 [1.0]		
Skin, Control Dermis	(20)	(20)	(20)
Inflammation, Chronic Active			4 [1.0]
Skin, Control Epidermis	(20)	(20)	(20)
Hyperkeratosis		1 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

TEF TRANSGENICS (TCDD)

Time Report Requested: 13:12:56

Route: SKIN APPLICATION

CAS Number: 1746-01-6

First Dose M/F: NA / 04/21/03

Species/Strain: MICE/TG.AC HEMI

Lab: BAT

0 NG/KG	121 NG/KG	760 NG/KG
TGAC (FVB/N) HEMIZYGOUS MICE FEMALE		
Hyperplasia, Squamous Skin, Site Of Application	1 [1.0] (20)	(20)
Fibrosis	1 [2.0]	
Hyperkeratosis		1 [1.0]
Hyperplasia, Squamous	1 [3.0]	14 [2.5]
Inflammation, Chronic Active	2 [1.0]	20 [2.5]
Skin, Soa No Mass	(20)	(17)
Hyperplasia, Mast Cell	1 [2.0]	
Hyperplasia, Squamous	1 [1.0]	10 [1.3]
Inflammation, Granulomatous		1 [1.0]
Inflammation, Chronic Active	3 [1.0]	13 [1.5]
Ulcer	1 [1.0]	
MUSCULOSKELETAL SYSTEM		
None		
NERVOUS SYSTEM		
None		
RESPIRATORY SYSTEM		
Lung	(20)	(20)
Alveolar Epithelium, Hyperplasia		1 [2.0]
Alveolus, Infiltration Cellular, Histiocyte		1 [3.0]
Bronchiole, Inflammation		2 [1.0]
Interstitial, Inflammation	1 [1.0]	3 [2.0]
Perivascular, Infiltration Cellular, Mixed Cell		1 [1.0]
Perivascular, Inflammation	2 [1.0]	2 [1.0]
Serosa, Inflammation, Chronic Active	7 [1.0]	4 [1.8]
SPECIAL SENSES SYSTEM		
None		
URINARY SYSTEM		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-WEEK

TEF TRANSGENICS (TCDD)

Time Report Reqsted: 13:12:56

Route: SKIN APPLICATION

CAS Number: 1746-01-6

First Dose M/F: NA / 04/21/03

Species/Strain: MICE/TG.AC HEMI

Lab: BAT

TGAC (FVB/N) HEMIZYGOUS MICE FEMALE	0 NG/KG	121 NG/KG	760 NG/KG
Kidney	(0)	(0)	(2)
Renal Tubule, Dilatation			1 [2.0]
Renal Tubule, Vacuolization Cytoplasmic			1 [1.0]

*** END OF REPORT ***